查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1392001

範科尼貧血治療藥物市場：依治療類型、年齡層、階段、地區

Fanconi Anemia Drug Market, By Treatment Type, By Age Group, By Disease Stage, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年全球範可尼貧血治療市場估計為5.744億美元，預計到2030年將達到8.136億美元，2023年至2030年年複合成長率為5.1%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 5.744億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 5.10% 2030年市場規模預測 8.136 億美元
圖 1. 2023 年範可尼貧血藥物的全球市場佔有率（按地區分類）
範可尼貧血藥物市場-IMG1

範可尼貧血治療旨在治療範可尼貧血的症狀和潛在的遺傳異常，範可尼貧血是一種罕見的遺傳性疾病，其特徵是骨髓衰竭、出生缺陷和癌症風險增加。或藥物治療和目前正在研究的治療方法。許多器官系統都受到範可尼貧血的影響。範可尼貧血是由缺陷基因引起的，該基因會損害細胞並阻止細胞修復受損的 DNA。它幾乎影響身體的每個器官。也稱為遺傳性再生障礙性貧血。

市場動態：

科學研究和分子機制知識的不斷進步預計將推動預測期內範可尼貧血治療藥物市場的成長。此外，在預測期內，未滿足的醫療需求將繼續推動範可尼貧血治療市場的成長。這一因素推動了研究和開發配合措施，以尋找控制和治療 FA 的有效療法。在預測期內，疾病修正治療的開拓可能為全球範可尼貧血治療市場創造新的機會。我們有機會創造能夠解決與 FA 相關的遺傳變化和分子機制的緩解疾病藥物。例如，2022年5月17日，生物技術公司Jasper Therapeutics, Inc.宣布將加入史丹佛大學醫學院確定性和治療醫學中心（CDCM），研究JPS191作為調理劑治療範可尼貧血。宣布資助研究中第一位患者的給藥。根據該協議，史丹佛大學醫學院正在對 JSP191 進行一項 1/2 期臨床試驗 (NCT04784052)，用於治療患有骨髓衰竭且需要非兄弟姐妹供體同種異體移植的範可尼貧血患者。

本研究的主要特點

  • 本報告對全球範可尼貧血治療藥物市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率（CAGR%）。
  • 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球範可尼貧血治療藥物市場的主要企業。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
  • 全球範可尼貧血治療藥物市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 相關人員可以透過用於分析全球範可尼貧血治療藥物市場的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

  • 市場動態
    • 促進因素
  • 科學研究和分子機制理解的不斷進步
  • 大量未滿足的醫療需求
    • 抑制因素
  • 缺乏公認的治療方法
    • 機會
  • 疾病修正治療的開發
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章 全球範可尼貧血治療藥物市場 -冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章 全球範可尼貧血治療藥物市場，依治療類型，2018-2030

  • 造血生長因子
  • 基因治療
  • 幹細胞移植
  • 其他治療方法

第6章 全球範可尼貧血治療市場，依年齡層，2018-2030

  • 兒童患者
  • 成年患者

第7章 全球範可尼貧血治療市場，依階段，2018-2030

  • 階段
  • 晚期

第8章 全球範可尼貧血治療藥物市場，按地區，2018-2030

  • 北美洲
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第9章 競爭形勢

  • Foresee Pharmaceuticals Co., Ltd.
  • Rocket Pharmaceuticals Inc.
  • Amgen
  • Novartis AG
  • Gilead Sciences, Inc.（Kite Pharma, Inc.）
  • Celgene Corporation（Juno Therapeutics）
  • Spark Therapeutics
  • UniQure NV
  • Bluebird Bio, Inc.
  • PTC Therapeutics
  • Orchard Therapeutics Limited
  • GlaxoSmithKline Plc.
  • Aurora Biopharma, Inc.
  • Pfizer, Inc.
  • Autolus Therapeutics

第10章 章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5909

Global fanconi anemia drug market is estimated to be valued at US$ 574.4 Mn in 2023, and is expected to reach US$ 813.6 Mn by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 574.4 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.10% 2030 Value Projection: US$ 813.6 Mn
Figure 1. Global Fanconi Anemia Drug Market Share (%), By Region, 2023
Fanconi Anemia Drug Market - IMG1

The fanconi anemia drugs are pharmaceutical therapies and treatments that have been created or are currently being researched with the goal of treating the symptoms and underlying genetic abnormalities of fanconi anemia, a rare genetic disorder that is marked by bone marrow failure, congenital defects, and an increased risk of developing cancer. Numerous organ systems are impacted by fanconi anemia. Fanconi anemia results from a defective gene that harms cells, and prevents them from mending damaged DNA. It has an impact on practically all body organs. It is also known as aplastic anemia that is hereditary.

Market Dynamics:

Continuous advancements in scientific research and knowledge about molecular mechanisms are expected to drive the global fanconi anemia drug market growth over the forecast period. Substantial unmet medical need will also continue to fuel growth of the global fanconi anemia drug market over the forecast period. This element motivates efforts in research and development to find efficient therapeutics for the control and treatment of FA. Development of disease-modifying therapies will create new opportunities for the global fanconi anemia drug market over the forecast period. There are opportunities for the creation of disease-modifying medications that can deal with the genetic alterations and molecular mechanisms connected to FA. For instance, on May 17, 2022, Jasper Therapeutics, Inc., a biotechnology company, announced the dosing of the first patient in its sponsored research of the Center for Definitive and Curative Medicine (CDCM) at the Stanford University School of Medicine for the study of JPS191 as a conditioning agent in the treatment of Fanconi Anemia. In accordance with the sponsored research agreement, Stanford Medicine is conducting a Phase 1/2 clinical trial (NCT04784052) utilizing JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.

Key features of the study:

  • This report provides in-depth analysis of the global fanconi anemia drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global fanconi anemia drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Foresee Pharmaceuticals Co., Ltd., Rocket Pharmaceuticals Inc., Amgen, Novartis AG, Gilead Sciences, Inc. (Kite Pharma, Inc.), Celgene Corporation (Juno Therapeutics), Spark Therapeutics, UniQure N.V, Bluebird Bio, Inc., PTC Therapeutics, Orchard Therapeutics Limited, GlaxoSmithKline Plc., Aurora Biopharma, Inc., Pfizer, Inc. and Autolus Therapeutics
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global fanconi anemia drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fanconi anemia drug market

Detailed Segmentation:

  • By Treatment Type:
    • Hematopoietic Growth Factors
    • Gene Therapy
    • Stem Cell Transplantation
    • Other Therapies
  • By Age Group:
    • Pediatric Patients
    • Adult Patients
  • By Disease Stage:
    • Early-stage Disease
    • Advanced-stage Disease
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Foresee Pharmaceuticals Co., Ltd.
    • Rocket Pharmaceuticals Inc.
    • Amgen
    • Novartis AG
    • Gilead Sciences, Inc. (Kite Pharma, Inc.)
    • Celgene Corporation (Juno Therapeutics)
    • Spark Therapeutics
    • UniQure N.V
    • Bluebird Bio, Inc.
    • PTC Therapeutics
    • Orchard Therapeutics Limited
    • GlaxoSmithKline Plc
    • Aurora Biopharma, Inc.
    • Pfizer, Inc.
    • Autolus Therapeutics

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Fanconi Anemia Drug, By Treatment Type
    • Market Fanconi Anemia Drug, By Age Group
    • Market Fanconi Anemia Drug, By Disease Stage
    • Market Fanconi Anemia Drug, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Continuous advancements in scientific research and understanding of the molecular mechanisms
  • Substantial unmet medical need
    • Restraints
  • Lack of recognized therapies
    • Opportunities
  • Development of Disease-Modifying Therapies
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Fanconi Anemia Drug Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Fanconi Anemia Drug Market, By Treatment Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hematopoietic Growth Factors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Stem Cell Transplantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Other Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Fanconi Anemia Drug Market, By Age Group, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Pediatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Fanconi Anemia Drug Market, By Disease Stage, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Early-stage Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Advanced-stage Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Fanconi Anemia Drug Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2018 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • South Africa
  • North Africa
  • Central Africa

9. Competitive Landscape

  • Foresee Pharmaceuticals Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Rocket Pharmaceuticals Inc.
  • Amgen
  • Novartis AG
  • Gilead Sciences, Inc. (Kite Pharma, Inc.)
  • Celgene Corporation (Juno Therapeutics)
  • Spark Therapeutics
  • UniQure N.V
  • Bluebird Bio, Inc.
  • PTC Therapeutics
  • Orchard Therapeutics Limited
  • GlaxoSmithKline Plc.
  • Aurora Biopharma, Inc.
  • Pfizer, Inc.
  • Autolus Therapeutics
  • Analyst Views

10. Section

  • Research Methodology
  • About us